| Autore |
Mannhold Raimund
|
| Pubbl/distr/stampa |
Newark : , : John Wiley & Sons, Incorporated, , 2023
|
| Descrizione fisica |
1 online resource (459 pages)
|
| Disciplina |
615.7
|
| Altri autori (Persone) |
BuschmannHelmut
BachhavYogeshwar
HolenzJörg
|
| Collana |
Methods and Principles in Medicinal Chemistry Ser.
|
| ISBN |
3-527-82785-4
3-527-82786-2
|
| Formato |
Materiale a stampa  |
| Livello bibliografico |
Monografia |
| Lingua di pubblicazione |
eng
|
| Nota di contenuto |
Cover -- Title Page -- Copyright -- Contents -- A Personal Foreword -- Preface -- Chapter 1 Basics of Targeted Drug Delivery -- 1.1 Introduction -- 1.1.1 Concept of Bioavailability and Therapeutic Index -- 1.2 Targeted Drug Delivery -- 1.3 Strategies for Drug Targeting -- 1.3.1 Passive Targeting -- 1.3.1.1 Reticuloendothelial System (RES) System -- 1.3.1.2 Enhanced Permeability and Retention (EPR) Effect -- 1.3.1.3 Localized Delivery -- 1.3.2 Active Targeting -- 1.3.3 Physical Targeting -- 1.3.3.1 Ultrasound for Targeting -- 1.3.3.2 Magnetic Field for Targeting -- 1.4 Therapeutic Applications of Targeted Drug Delivery -- 1.4.1 Diabetes Management -- 1.4.2 Neurological Diseases -- 1.4.3 Cardiovascular Diseases -- 1.4.4 Respiratory Diseases -- 1.4.5 Cancer Indications -- 1.5 Targeted Dug‐Delivery Products -- 1.6 Challenges -- 1.6.1 Passive Targeting and EPR Effect -- 1.6.2 Active Targeting -- 1.7 Scale‐up and Challenges -- 1.8 Current Status -- 1.9 Conclusion and Prospects -- References -- Chapter 2 Addressing Unmet Medical Needs Using Targeted Drug‐Delivery Systems: Emphasis on Nanomedicine‐Based Applications -- 2.1 Introduction -- 2.2 Targeted Drug‐Delivery Systems for Unmet Medical Needs -- 2.2.1 Targeting Ligands -- 2.2.1.1 Small Molecules as Targeting Ligands -- 2.2.1.2 Aptamers as Targeting Ligands -- 2.2.1.3 Antibodies as Targeting Ligands -- 2.2.1.4 Lectins as Targeting Ligands -- 2.2.1.5 Lactoferrins as Targeting Ligands -- 2.2.2 Targeting Approaches -- 2.2.2.1 Disease‐Based Targeting -- 2.2.2.2 Location‐Based Targeting -- 2.3 Regulatory Aspects and Clinical Perspectives -- 2.4 Conclusion and Future Outlook -- References -- Chapter 3 Nanocarriers‐Based Targeted Drug Delivery Systems: Small and Macromolecules -- 3.1 Nanocarriers (Nanomedicine) - Overview and Role in Targeted Drug Delivery -- 3.2 Passive Targeting Approaches.
3.2.1 Enhanced Permeability and Retention‐Effect‐Based Targeting -- 3.3 Active Targeting Approaches -- 3.4 Stimuli Responsive Targeted NCs -- 3.4.1 Redox Stimuli Responsive Targeted NCs -- 3.4.2 pH Stimuli Responsive Targeted NCs -- 3.4.3 Enzyme Stimuli Responsive Targeted NCs -- 3.4.4 Temperature Stimuli Responsive Targeted NCs -- 3.4.5 Ultrasound Stimuli Responsive Targeted NCs -- 3.4.6 Magnetic Field Stimuli Responsive Targeted NCs -- 3.5 Conclusion and Future Prospects -- References -- Chapter 4 Liposomes as Targeted Drug‐Delivery Systems -- 4.1 Introduction -- 4.2 Liposome Commercial Landscape -- 4.3 Important Considerations in Development and Characterization of Liposomes -- 4.3.1 Selection of Lipids -- 4.3.2 Drug : Lipid Ratio -- 4.3.3 PEGylation -- 4.3.4 Ligand Anchoring -- 4.3.5 Drug‐Loading Techniques -- 4.3.6 Physicochemical Characterization -- 4.3.7 Manufacturing Process -- 4.3.8 Product Stability -- 4.4 Targeted Delivery of Liposomes -- 4.4.1 Passive Targeting -- 4.4.2 Active‐Targeted Delivery -- 4.4.2.1 Cancer Cell Targeting -- 4.4.2.2 Tumor Endothelium Targeting -- 4.5 Recent Clinical Trials with Liposomes with Investigational Liposome Candidates -- 4.6 Factors Influencing the Clinical Translation of Liposomes for Targeted Delivery -- 4.7 Conclusions and Future of Prospects of Targeted Liposomal‐Delivery Systems -- References -- Chapter 5 Antibody-Drug Conjugates: Development and Applications -- 5.1 Introduction -- 5.2 Design of ADCs -- 5.2.1 Antibody -- 5.2.2 Linker -- 5.2.3 Payload -- 5.3 Mechanism of Action -- 5.4 Pharmacokinetic Considerations for ADCs -- 5.4.1 Heterogeneity of ADCs -- 5.4.2 Bioanalytical Considerations for ADCs -- 5.4.3 Pharmacokinetic Parameters of ADCs -- 5.4.3.1 Absorption -- 5.4.3.2 Distribution -- 5.4.3.3 Metabolism and Elimination -- 5.5 Applications of ADCs -- 5.5.1 Approved ADCs in the Market.
5.5.1.1 Gemtuzumab Ozogamicin -- 5.5.1.2 Brentuximab Vedotin -- 5.5.1.3 Ado‐Trastuzumab Emtansine (T‐DM1) -- 5.5.1.4 Inotuzumab Ozogamicin -- 5.5.1.5 Polatuzumab Vedotin‐piiq -- 5.5.1.6 Enfortumab Vedotin -- 5.5.1.7 Trastuzumab Deruxtecan -- 5.5.2 Use of ADCs in Rheumatoid Arthritis -- 5.5.3 Use of ADCs in Bacterial Infections -- 5.5.4 Use of ADCs in Ophthalmology -- 5.6 Resistance of ADC -- 5.7 Regulatory Aspects for ADCs -- 5.7.1 Role of ONDQA -- 5.7.2 Role of OBP -- 5.8 Conclusion and Future Direction -- References -- Chapter 6 Gene‐Directed Enzyme-Prodrug Therapy (GDEPT) as a Suicide Gene Therapy Modality for Cancer Treatment -- 6.1 Introduction -- 6.2 GDEPT for Difficult‐to‐Treat Cancers -- 6.2.1 High‐Grade Gliomas (HGGs) -- 6.2.2 Triple‐Negative Breast Cancer (TNBC) -- 6.2.3 Other Cancers -- 6.3 Novel Enzymes for GDEPT -- 6.4 Conclusions -- References -- Chapter 7 Targeted Prodrugs in Oral Drug Delivery -- 7.1 Introduction -- 7.1.1 Classic vs. Modern Prodrug Approach -- 7.2 Modern, Targeted Prodrug Approach -- 7.2.1 Prodrug Approach‐Targeting Enzymes -- 7.2.1.1 Valacyclovirase‐Mediated Prodrug Activation -- 7.2.1.2 Phospholipase A2‐Mediated Prodrug Activation -- 7.2.1.3 Antibody, Gene, and Virus‐Directed Enzyme-Prodrug Therapy -- 7.2.2 Prodrug Approach Targeting Transporters -- 7.2.2.1 Peptide Transporter 1 -- 7.2.2.2 Monocarboxylate Transporter Type 1 -- 7.2.2.3 Bile Acid Transporters -- 7.3 Computational Approaches in Targeted Prodrug Design -- 7.4 Discussion -- 7.5 Future Prospects and Clinical Applications -- 7.6 Conclusion -- References -- Chapter 8 Exosomes for Drug Delivery Applications in Cancer and Cardiac Indications -- 8.1 Extracellular Vesicles: An Overview -- 8.1.1 Evolution of Exosomes -- 8.1.2 Exosomes as Delivery Vehicles for Therapeutics -- 8.1.2.1 Endogenous Loading Methods -- 8.1.2.2 Exogenous Loading Methods.
8.2 Exosomes as Cancer Therapeutics -- 8.2.1 Influence of Donor Cells -- 8.2.2 Different Therapeutic Cargo Explored in Cancer Therapy -- 8.2.2.1 Delivery of Proteins and Peptides -- 8.2.2.2 Delivery of Chemotherapeutic Cargo -- 8.2.2.3 Delivery of RNA -- 8.3 Exosome Based Drug Delivery for Cardiovascular Diseases -- 8.3.1 Delivery of Cardioprotective RNAs -- 8.3.2 Exosomes Modified with Cardiac Targeting Peptides -- 8.4 Clinical Evaluations and Future Aspects -- 8.5 Conclusion -- Acknowledgments -- References -- Chapter 9 Delivery of Nucleic Acids, Such as siRNA and mRNA, Using Complex Formulations -- 9.1 Introduction -- 9.2 NA‐Based Complex Delivery System -- 9.2.1 Classical NA‐Based Complex Delivery System -- 9.2.1.1 Polymer‐Based NA‐Complex Delivery System -- 9.2.1.2 Lipid‐Based Complex NA Delivery System -- 9.2.1.3 Peptide‐Based Complex NA Delivery System -- 9.2.2 Advanced NA‐Based Complex Delivery Systems -- 9.2.2.1 Inorganic and Hybrid NPs -- 9.2.2.2 Self‐Assembled NA Nanostructures -- 9.2.2.3 Exosomes and NanoCells -- 9.3 Applications of NA‐Complex Delivery Systems -- 9.3.1 Genome Editing -- 9.3.2 Cancer Therapy -- 9.3.3 Protein Therapy -- 9.4 Future Prospective -- 9.5 Conclusion -- Acknowledgments -- References -- Chapter 10 Application of PROTAC Technology in Drug Development -- 10.1 Introduction -- 10.2 Design of PROTACS: A Brief Overview -- 10.3 Therapeutic Applications of PROTACs -- 10.3.1 Cancer -- 10.3.2 Neurodegenerative Disorders -- 10.3.3 Immunological Diseases -- 10.3.4 Viral Infections -- 10.4 Challenges and Limitations in the Development PROTACs -- 10.5 Future Perspectives -- References -- Chapter 11 Metal Complexes as the Means or the End of Targeted Delivery for Unmet Needs -- 11.1 Introduction -- 11.2 Class 1: Chaperones -- 11.2.1 Chaperones that Protect Drugs -- 11.2.2 Delivery to the Cells or Environments to Be Targeted.
11.2.3 Release from the Metal Where and When Required -- 11.3 Class 2: Active Metal Complexes -- 11.3.1 Targeted Platinum Agents -- 11.4 Class 3: Dual‐Threat Metal Complexes -- 11.5 Targeting Strategies: The Chemical and Physical Environment -- 11.5.1 Hypoxia -- 11.5.2 pH‐Based Targeting -- 11.5.3 The EPR Effect -- 11.6 Targeting Strategies: Transporters -- 11.7 Targeting Strategies: Enzyme Activation -- 11.8 Other Targeting Strategies -- 11.9 Conclusions -- References -- Chapter 12 Formulation of Peptides for Targeted Delivery -- 12.1 Introduction -- 12.2 Peptides Used in Cancer Therapy -- 12.2.1 Lung Cancer -- 12.2.2 Melanoma -- 12.2.3 Pancreatic Cancer -- 12.2.4 Brain Cancer -- 12.2.5 Breast Cancer -- 12.2.6 Leukemia -- 12.3 Peptide‐Targeting Based on Site of Action -- 12.3.1 Topical Delivery of Peptides -- 12.3.2 Ocular Delivery of Peptides -- 12.3.3 Brain Delivery of Peptides -- 12.3.4 Lung‐Targeted Delivery of Peptides -- 12.4 Conclusion and Future Prospects -- References -- Chapter 13 Antibody‐Based Targeted T‐Cell Therapies -- 13.1 Introduction -- 13.2 Immune‐Directed Cancer Cell Death -- 13.3 Immunotherapy Strategies in Cancer -- 13.4 T‐Cell Therapy -- 13.5 Naturally Occurring T Cells -- 13.6 Genetically Modified Occurring T Cells -- 13.7 Clinical Implication of T‐Cell and CAR‐T‐Cell Therapy: -- 13.8 Antibody‐Induced T‐Cell Therapy -- 13.9 A Bispecific Antibody (BsAbs)‐Induced T‐Cell Therapy -- 13.10 Formats of BsAbs -- 13.11 Triomab Antibodies in T‐Cell Therapy -- 13.12 Bispecific Antibodies in T‐Cell Therapy -- 13.13 Clinically Approved T‐Cell‐Activating Antibodies -- 13.14 Prospects -- 13.15 Conclusion -- References -- Chapter 14 Devices for Active Targeted Delivery: A Way to Control the Rate and Extent of Drug Administration -- 14.1 Introduction -- 14.2 Macrofabricated Devices - Drug Infusion Pumps -- 14.2.1 Peristaltic Pumps.
14.2.2 Gas‐Driven Pumps.
|
| Record Nr. | UNINA-9910632495303321 |
Info
Innovative dosage forms : design and development at early stage / / edited by Yogeshwar Bachhav
